Use of High‐Dose, Twice‐Yearly Albendazole and Ivermectin to SuppressWuchereria bancroftiMicrofilarial Levels

Authors:
  • HDHousseini Dolo
    Housseini Dolo
  • SKSiaka Konate
    Siaka Konate
  • SCSiaka Y. Coulibaly
    Siaka Y. Coulibaly
  • DSDramane Sanogo
    Dramane Sanogo
  • LSLamine Soumaoro
    Lamine Soumaoro
  • MCMichel E. Coulibaly
    Michel E. Coulibaly
  • SDSalif Seriba Doumbia
    Salif Seriba Doumbia
  • ADAbdallah A. Diallo
    Abdallah A. Diallo
  • STSekou F. Traore
    Sekou F. Traore
  • AKAdama Diaman Keita
    Adama Diaman Keita
Publisher website
Google Scholar
Abstract
Annual mass treatment with albendazole and ivermectin is the mainstay of current strategies to interrupt transmission of Wuchereria bancrofti in Africa. More-effective microfilarial suppression could potentially reduce the time necessary to interrupt transmission, easing the economic burden of mass treatment programs in countries with limited resources. To determine the effect of increased dose and frequency of albendazole-ivermectin treatment on microfilarial clearance, 51 W. bancrofti microfilaremic residents of an area of W. bancrofti endemicity in Mali were randomized to receive 2 doses of annual, standard-dose albendazole-ivermectin therapy (400 mg and 150 μg/kg; n = 26) or 4 doses of twice-yearly, increased-dose albendazole-ivermectin therapy (800 mg and 400 μg/kg; n = 25). Although microfilarial levels decreased significantly after therapy in both groups, levels were significantly lower in the high-dose, twice-yearly group at 12, 18, and 24 months. Furthermore, there was complete clearance of detectable microfilariae at 12 months in the 19 patients in the twice-yearly therapy group with data available at 12 months, compared with 9 of 21 patients in the annual therapy group (P < .001, by Fisher's exact test). This difference between the 2 groups was sustained at 18 and 24 months, with no detectable microfilariae in the patients receiving twice-yearly treatment. Worm nests detectable by ultrasonography and W. bancrofti circulating antigen levels, as measured by enzyme-linked immunosorbent assay, were decreased to the same degree in both groups at 24 months, compared with baseline. These findings suggest that increasing the dosage and frequency of albendazole-ivermectin treatment enhances suppression of microfilariae but that this effect may not be attributable to improved adulticidal activity.

This publication has 18 references indexed in Scilit: